Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Financial statements
Income statement, balance sheet, and cash flow for Corbus Pharmaceuticals Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.88 | |
| Cost of Revenue | 0.00↓100.0% | 0.60 | 0.00↓100.0% | 1↓9.2% | 2 | |
| Gross Profit | 0.00↑100.0% | -0.60 | 0.00↑100.0% | -1↓96.4% | -0.76 | |
| Operating Expenses | ||||||
| R&D Expenses | 70↑117.5% | 32↑3.4% | 31↑93.1% | 16↓55.7% | 36 | |
| General & Administrative Expenses | 15↓7.8% | 16↑18.6% | 14↓25.6% | 19↓8.5% | 20 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 15↓7.8% | 16↑18.6% | 14↓25.6% | 19↓8.5% | 20 | |
| Other Expenses | 0.00↑100.0% | -0.60 | 0.00↑100.0% | -1↑9.2% | -2 | |
| Operating Expenses | 85↑77.3% | 48↑6.8% | 45↑35.2% | 33↓39.6% | 55 | |
| Total Costs & Expenses | 85↑75.1% | 49↑8.1% | 45↑29.4% | 35↓38.7% | 57 | |
| Operating Results | ||||||
| Operating Income | -85↓75.1% | -49↓8.1% | -45↓29.4% | -35↑37.8% | -56 | |
| Depreciation & Amortization | 0.23↓61.2% | 0.60↓6.4% | 0.64↓56.9% | 1↓9.2% | 2 | |
| EBITDA | -78↓107.5% | -38↑5.9% | -40↓3.6% | -39↑28.7% | -54 | |
| EBIT | -79↓104.9% | -38↑5.9% | -41↓1.3% | -40↑28.2% | -56 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↑24.6% | 4↑251.8% | -3↓37.1% | -2↓16.5% | -2 | |
| Interest Income | 6↓12.4% | 6 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 2↓36.0% | 3↑37.1% | 2↑16.5% | 2 | |
| Non-Operating Income | -7↑34.8% | -10↓139.7% | -4↓180.5% | 5 | 0.00 | |
| Other Income / Expenses | 7↓20.4% | 9↑1695.8% | 0.47↑106.3% | -8↓172.6% | 10 | |
| Income Before Tax | -79↓95.3% | -40↑9.9% | -45↓5.3% | -42↑7.2% | -46 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -79↓95.3% | -40↑9.9% | -45↓5.3% | -42↑7.2% | -46 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -79↓95.3% | -40↑9.9% | -45↑20.1% | -56↓22.6% | -46 | |
| Bottom-Line Net Income | -79↓95.3% | -40↑9.9% | -45↓5.3% | -42↑7.2% | -46 | |
| EPS (Basic) | -5.90↓60.3% | -3.68↑64.3% | -10.31↓1.6% | -10.15↑8.6% | -11.11 | |
| EPS (Diluted) | -5.90↓60.3% | -3.68↑64.3% | -10.31↓1.6% | -10.15↑8.6% | -11.11 | |
| Weighted Average Shares | 13↑22.0% | 11↑152.3% | 4↑3.7% | 4↑1.7% | 4 | |
| Weighted Average Diluted Shares | 13↑22.0% | 11↑152.2% | 4↑3.8% | 4↑1.7% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.